U.S. law enforcers use biomarkers to track DUI repeat offenders; HistoRx licenses melanoma biomarker assay from Yale University;

> Researchers discover a link between nutrient biomarker patterns and variance in cognitive function and brain volume in elderly subjects. Abstract

> Sciclips launches diagnostic and prognostic cancer biomarker database. Article

> Pacific Biomarkers and Clinigene collaborate to provide biomarker services for the biopharma industry. Release

> Protein biomarker assay company Aushon BioSystems raises $2 million in equity. Story

> Researchers develop highly sensitive nanosensors to detect extremely small concentrations of biomarkers. Abstract

> Japanese team identifies a new plasma biomarker of Alzheimer's disease using metabolomics technology. Abstract

> U.S. law enforcers use biomarkers to track DUI repeat offenders. Article

> HistoRx licenses melanoma biomarker assay from Yale University. Release

> MR-proANP may have potential as a biomarker in preeclampsia. Abstract

> Autism Speaks funds biomarker studies for identifying infants at risk for developing autism. Announcement

> Plasma citrulline, a nonessential amino acid, could be a biomarker in pediatric patients with bowel dysfunction. Abstract

> Chinese researchers assess XAF1 as a possible prognostic biomarker and therapeutic target in squamous cell lung cancer. Abstract

> Researchers demonstrate that microRNA could be a potential diagnostic and prognostic pancreatic cancer biomarker. Abstract

> Angiopoietins can predict the outcome in cerebral malaria. Abstract

And Finally... Pacific Biomarkers promotes Dr. Amar Sethi from vice president of research and development to chief scientific officer. Release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.